详情页

资源类型：

文章类型：

作者：

Shi, Yuankai[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] * ; Hu, Xingsheng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Zhang, Shucai[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Lv, Dongqing[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Zhang, Yiping[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Yu, Qitao[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Wu, Lin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Liu, Li[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Wang, Xiang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Ma, Zhiyong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Cheng, Ying[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Niu, Hongrui[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Wang, Dong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Feng, Ji Feng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Huang, Cheng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Liu, Chunling[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Zhao, Hui[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Li, Jingzhang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Zhang, Xiaodong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ; Jiang, Yong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20] ;

机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targeted, Natl Clin Res Ctr Canc, Canc Hosp,Natl Canc Ctr, Beijing, Peoples R China [2]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China [3]Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China [4]Wenzhou Med Univ, Taizhou Hosp, Dept Resp Med, Linhai, Zhejiang, Peoples R China [5]Zhejiang Canc Hosp, Dept Thorac Med Oncol, Hangzhou, Peoples R China [6]Tumor Hosp Guangxi Zhuang Autonomous Reg, Dept Chemotherapy 2, Nanning, Peoples R China [7]Cent South Univ, Dept Thorac Med Oncol, Hunan Canc Hosp, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Peoples R China [8]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Thorac Oncol,Canc Ctr, Wuhan, Peoples R China [9]XuZhou Cent Hosp, Dept Med Oncol, Xuzhou, Jiangsu, Peoples R China [10]Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Hennan Canc Hosp, Zhengzhou, Peoples R China [11]Jilin Canc Hosp, Changchun, Peoples R China [12]Xinxiang Med Univ, Dept Oncol, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China [13]Third Mil Med Univ, Hosp Affiliated 3, Chongqing, Peoples R China [14]Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China [15]Fujian Med Univ, Fujian Canc Hosp, Affiliated Canc Hosp, Fuzhou, Peoples R China [16]Xinjiang Med Univ, Dept Pulm Med, Canc Hosp, Urumqi, Peoples R China [17]Anhui Univ, Dept Resp Med, Hosp 2, Hefei, Peoples R China [18]Liuzhou Peoples Hosp, Dept Med Oncol, Liuzhou, Peoples R China [19]Nantong Canc Hosp, Dept Med Oncol, Nantong, Peoples R China [20]Shanghai Allist Pharmaceut Co Ltd, Clin Affairs & Regulatory Dept, Shanghai, Peoples R China

出处：

DOI：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院分区：

出版当年[2020]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2020]版：

Q1 ONCOLOGY

最新[2024]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targeted, Natl Clin Res Ctr Canc, Canc Hosp,Natl Canc Ctr, Beijing, Peoples R China [2]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China [3]Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China [4]Wenzhou Med Univ, Taizhou Hosp, Dept Resp Med, Linhai, Zhejiang, Peoples R China [5]Zhejiang Canc Hosp, Dept Thorac Med Oncol, Hangzhou, Peoples R China [6]Tumor Hosp Guangxi Zhuang Autonomous Reg, Dept Chemotherapy 2, Nanning, Peoples R China [7]Cent South Univ, Dept Thorac Med Oncol, Hunan Canc Hosp, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Peoples R China [8]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Thorac Oncol,Canc Ctr, Wuhan, Peoples R China [9]XuZhou Cent Hosp, Dept Med Oncol, Xuzhou, Jiangsu, Peoples R China [10]Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Hennan Canc Hosp, Zhengzhou, Peoples R China [11]Jilin Canc Hosp, Changchun, Peoples R China [12]Xinxiang Med Univ, Dept Oncol, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China [13]Third Mil Med Univ, Hosp Affiliated 3, Chongqing, Peoples R China [14]Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China [15]Fujian Med Univ, Fujian Canc Hosp, Affiliated Canc Hosp, Fuzhou, Peoples R China [16]Xinjiang Med Univ, Dept Pulm Med, Canc Hosp, Urumqi, Peoples R China [17]Anhui Univ, Dept Resp Med, Hosp 2, Hefei, Peoples R China [18]Liuzhou Peoples Hosp, Dept Med Oncol, Liuzhou, Peoples R China [19]Nantong Canc Hosp, Dept Med Oncol, Nantong, Peoples R China [20]Shanghai Allist Pharmaceut Co Ltd, Clin Affairs & Regulatory Dept, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study.

文献详情